HCM
JUNO

Highbridge Capital Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Highbridge Capital Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-7,150
Closed -$382K – 1970
2015
Q2 		$382K Buy
+7,150
New +$379K ﹤0.01% 1060

Other funds holding JUNO

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Highbridge Capital Management's JUNO Position: Q3 2015 in Review

Highbridge Capital Management sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2015, closing a stake of 7,150 shares — an estimated $382K sold.

Highbridge Capital Management first reported a position in JUNO in Q2 2015 and held it in 1 quarter. The position peaked at $382K in Q2 2015. 132 funds tracked by Wall St. Rank hold JUNO as of Q3 2015.

  • Highbridge Capital Management reported no remaining Juno Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • Highbridge Capital Management sold 7,150 Juno Therapeutics, Inc. shares in Q3 2015, an estimated $382K.
  • Highbridge Capital Management first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 1 quarter.
  • Highbridge Capital Management's Juno Therapeutics, Inc. position peaked at $382K in Q2 2015.
  • 132 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2015.

Based on Highbridge Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.